Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 18/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639461 | 0.89 | ROCK2 (0.77) | KDRROCK2ROCK1 | |
| SCHEMBL17041163 | 0.87 | ROCK2 (0.71) | KDRROCK2ROCK1 | |
| SCHEMBL18114589 | 0.86 | ROCK2 (0.69) | ROCK2ROCK1 | |
| SCHEMBL17041146 | 0.86 | ROCK2 (0.75) | KDRROCK2ROCK1 | |
| SCHEMBL15639264 | 0.85 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL32670264 | 0.85 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL15639035 | 0.85 | ROCK2 (0.70) | ROCK2ROCK1 | |
| SCHEMBL15638684 | 0.85 | ROCK2 (0.71) | ROCK2ROCK1 | |
| SCHEMBL15639870 | 0.84 | ROCK2 (0.70) | KDRROCK2ROCK1 | |
| SCHEMBL15639833 | 0.84 | ROCK2 (0.85) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180339979-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-11-29 | — | — | US | claimed |
| EP-3283479-A1 | TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | claimed |
| WO-2016160833-A1 | TGF-β INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | claimed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3283479-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3283479-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20150252025-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150252025-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
| EP-2903618-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2903645-A2 | TREATMENT OF OCULAR DISORDERS | Kadmon Corporation, LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014055999-A2 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014055996-A2 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339979-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | KDR 355/4885ROCK2 1711/4885ROCK1 918/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | KDR 3466/4885ROCK2 1/4885ROCK1 4/4885 |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | ROCK2, KDR, FLT1 | KDR 2/4885ROCK2 1/4885ROCK1 5/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | KDR 2281/4885ROCK2 1/4885ROCK1 2/4885 |
| US-20150252025-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | KDR 1477/4885ROCK2 1/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.